secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-10-06T20:16:16+00:00
Accession:  0001104659-26-114055
Event type: debt
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Acura Pharmaceuticals borrows $200,000 from Abuse Deterrent Pharma; note principal reaches $11,294,279
--------------------------------------------------------------------------------

- Acura received $100,000 loans from Abuse Deterrent Pharma on Sept 18 and Oct 2, 2026, raising the secured note principal to $11,294,279.
- Accrued interest was about $1,365,000 as of Sept 30, 2026; the note bears 5.25%, with overdue amounts at 7.5%.
- Absent additional financing by mid-October 2026, Acura says it may scale back operations, furlough or lay off employees, terminate operations, or seek bankruptcy protection.
- Events of default include failure to pay principal or interest continuing 5 days, bankruptcy events, and inability to pay debts as they come due.
- Exhibit 99.1 lists Loans #51 through #66, including Loan #66 dated Oct 2, 2026 for $100,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926114055/0001104659-26-114055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926114055/tm2627130d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-114055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer